TITLE

Hold the Victory Parade

AUTHOR(S)
Paul, Reid
PUB. DATE
July 2011
SOURCE
Pharmaceutical Representative;Jul2011, Vol. 41 Issue 7, p5
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses updates in the pharmaceutical industry in the U.S. It mentions the ruling of the Supreme Court in PLIVA v. Mensing wherein the court sided with generic manufacturers, making generics a more dangerous option. It also discusses the adoption of a universal healthcare bill in Vermont.
ACCESSION #
63483061

 

Related Articles

  • High court rules on 'pay-for-delay' deals. HOLLAND, JESSE J. // Buffalo Law Journal;6/24/2013, Vol. 85 Issue 34, p4 

    The article reports on the 5-3 votes of the justices in the U.S. Supreme Court allowing the government to inspect and challenge the "pay-for-delay" deals between pharmaceutical corporations and their generic drug competitors.

  • Was it a surprise health care ruling or not? Crain, Keith // Crain's Detroit Business;7/2/2012, Vol. 28 Issue 27, p0006 

    The article reports on the five-four decision of the U.S. Supreme Court on upholding the Affordable Care Act, in which the court did not shared its decision with the White House. It says that the decision was one of the issues which polarized the country. It mentions that the health care...

  • Dust settles, industry reacts to aftershock of SCOTUS vote. Pedersen, Amanda // Medical Device Daily;7/1/2012, Vol. 16 Issue 127, p1 

    The article focuses on the aftermath of the U.S. Supreme Court's decision to uphold the Affordable Care Act. An overview of a report on the decision published by the Health Research Institute (HRI) of PriceWaterhouseCoopers (PwC) is provided. The implications of the law to the healthcare and...

  • CONSUMER MARKETING: Update.  // Medical Marketing & Media;Jan2012, Vol. 47 Issue 1, p23 

    The article offers news briefs related to healthcare and pharmaceutical industry in the U.S., mentioning the advertising campaign launch by Presbyterian Hospital, the results of a survey on attitudes towards advertising and the survey that pushes the therapeutic substitution of generics drugs.

  • Filling a Gap in Drug Safety. Peters, Rita // Pharmaceutical Technology;Aug2013, Vol. 37 Issue 8, p11 

    In this article, the author discusses several court cases related to pharmaceutical industry of the U.S. She mentions about the U.S. Supreme Court including Federal Trade Commission v. Actavis, Inc., et al, which is related to financial deals between innovator drug companies and generic...

  • Supreme Court Denies Review of State Law Restricting Data-Mining.  // Journal of AHIMA;2009, Vol. 80 Issue 8, p12 

    The article reports that the U.S. Supreme Court has refused to hear an appeal by health data-mining firms, that would reportedly block a New Hampshire law restricting the use of information related to physicians' prescribing habits. The New Hampshire law was passed in 2006, which reportedly made...

  • Other Clouds Forming Behind Supreme Court Ruling. Serebrov, Mari // BioWorld Insight;7/2/2012, Vol. 20 Issue 27, p2 

    The article offers information on the constitutionality of the U.S. Affordable Care Act (ACA) in the country's health care industry. It informs that after the U.S. Supreme Court's decision, many people invested for health care insurance. The article discusses the impact of the health care law on...

  • Has the Supreme Court Thrown Health Care Regulation into Disarray? A Comment on the Court's Reworking of the State Action Doctrine. KASS, COLIN R.; ABELES, SCOTT M.; INGRASSIA, JOHN // Antitrust Magazine;Fall2015, Vol. 30 Issue 1, p58 

    The article focuses on antitrust issues as well as health care regulation and state action doctrine in the U.S. It highlights Supreme Court's two state action cases involving health care wherein the court, in each case, has declined to immunize the health sector defendant and narrowed the state...

  • Pay To Delay. Silverman, Ed // Contract Pharma;Jan/Feb2014, Vol. 16 Issue 1, p28 

    The article focuses on the troubles being brought by pay-to-delay deals between generic and brand-name drugmakers in the pharmaceutical industry. Topics discussed include the ruling of the U.S. Supreme Court on whether such deals are illegal or not , the response of the U.S. Federal Trade...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics